Stem Cell Research in Ophthalmology

Age-related macular degeneration (AMD) affects approximately 19.8 million Americans aged 40 and older, according to the Centers for Disease Control and Prevention. For the subset of those patients with advanced dry AMD — geographic atrophy — there has been no way to restore retinal cells once they die. The photoreceptors and retinal pigment epithelium (RPE) simply do not regenerate on their own. That biological dead end is precisely what makes stem cell research one of the most consequential frontiers in ophthalmology.

Why the Eye Became a Proving Ground for Stem Cell Therapy

The eye offers three properties that make it unusually suited for stem cell transplantation. First, it is immunologically privileged — the blood-retina barrier limits immune surveillance, reducing the risk of graft rejection compared to transplants elsewhere in the body. Second, the target tissue is small and accessible; a surgeon can deliver cells to the subretinal space through standard vitreoretinal techniques. Third, the outcomes are measurable with extraordinary precision. Optical coherence tomography (OCT) can image retinal layers at micrometer resolution, and functional testing via microperimetry can track visual sensitivity over time.

These advantages help explain why, as of early 2024, the National Institutes of Health ClinicalTrials.gov registry lists more than 90 interventional trials involving stem cells and eye disease — spanning conditions from AMD to Stargardt disease to limbal stem cell deficiency.

RPE Cell Replacement for Macular Degeneration

The most advanced therapeutic programs target RPE cells, the single-layer tissue beneath the photoreceptors that keeps them alive and functioning. When RPE cells die in geographic atrophy, the photoreceptors above them follow.

Two broad strategies have emerged. One involves injecting a suspension of RPE cells derived from human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs) into the subretinal space. The other delivers those cells pre-seeded onto a bioengineered scaffold — essentially a tiny patch — that maintains the cells in a polarized monolayer mimicking their natural architecture.

The landmark Phase 1/2 trial led by the London Project to Cure Blindness, published in Nature Biotechnology in 2018, implanted an hESC-derived RPE patch in two patients with severe wet AMD. Both patients showed improved visual acuity that was sustained at 12 months, with integration of the patch confirmed by OCT imaging (Kashani et al., 2018, Science Translational Medicine). A separate California-based trial by Regenerative Patch Technologies reported similar structural integration in five patients with geographic atrophy.

The National Eye Institute (NEI), part of the NIH, has pursued its own autologous iPSC-RPE program. The approach takes a patient's own blood cells, reprograms them into iPSCs, differentiates those into RPE, and transplants the tissue back into the same patient — eliminating immunological mismatch entirely. NEI initiated a Phase 1 clinical trial for this autologous approach in patients with geographic atrophy (NCT04339764), a milestone in personalized regenerative medicine for eye disease.

Limbal Stem Cell Deficiency: A Success Story Already in Practice

Not all stem cell applications in ophthalmology remain experimental. Limbal stem cell deficiency (LSCD) — caused by chemical burns, Stevens-Johnson syndrome, or genetic conditions — destroys the stem cells at the corneal limbus responsible for maintaining a clear, healthy corneal surface. The result is painful opacity and vision loss.

In 2015, the European Medicines Agency approved Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells), making it the first stem cell therapy approved for any indication in the Western world (European Medicines Agency). The therapy involves taking a 1–2 mm biopsy from the patient's unaffected eye, expanding the limbal stem cells on a fibrin scaffold in a laboratory over roughly two to three weeks, and transplanting the resulting tissue onto the damaged cornea. Clinical data supporting approval showed a stable corneal surface in approximately 72% of treated eyes.

Photoreceptor Replacement: The Harder Problem

Replacing RPE is challenging enough. Replacing photoreceptors — the rods and cones themselves — represents a substantially more difficult goal because these cells must form synaptic connections with the existing retinal circuitry to transmit visual signals to the brain.

Research groups at institutions including University College London, the RIKEN Center for Biosystems Dynamics Research in Kobe, Japan, and the NEI have demonstrated that stem cell-derived photoreceptor precursors can integrate into the mouse retina and respond to light. Translating this to humans requires overcoming barriers of scale, synaptic integration, and long-term survival. Retinal organoids — three-dimensional structures grown from stem cells that self-organize into layered retinal tissue — have become a critical research tool, producing photoreceptor subtypes that more closely resemble mature human cells.

Risks and Regulatory Caution

The FDA has taken enforcement action against clinics offering unproven stem cell injections for eye disease. A widely reported 2017 case involved three patients at a Florida clinic who received bilateral intravitreal injections of autologous adipose-derived stem cells and suffered severe, permanent vision loss (New England Journal of Medicine, 2017). That episode underscored the difference between rigorously controlled clinical trials and unregulated commercial offerings. The FDA's regulatory framework classifies most stem cell-based therapies as biological products requiring premarket approval under Section 351 of the Public Health Service Act.

What Comes Next

The trajectory is clear even if the timeline is not. Autologous iPSC therapies could eventually eliminate rejection risk. Gene-edited stem cells may combine the advantages of cell replacement with targeted correction of inherited mutations — relevant for conditions like retinitis pigmentosa, where more than 100 causative genes have been identified. The convergence of stem cell biology, gene therapy, and advanced imaging positions ophthalmology at the leading edge of regenerative medicine — a field where the eye, once again, offers the clearest view of what is possible.

References

• National Eye Institute — NEI Autologous iPSC-RPE Clinical Trial
• ClinicalTrials.gov — Stem Cell Trials in Ophthalmology
• European Medicines Agency — Holoclar EPAR
• FDA — Framework for Regulation of Regenerative Medicine Products
• CDC — Age-Related Macular Degeneration Data
• Kuriyan et al., 2017, New England Journal of Medicine

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)